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A b s t r a c t  
A specific and efficient method using High Performance Liquid Chromatography (HPLC) has been 
developed to validate the pharmacokinetics of sustained-release formulation containing Isradipine. 
The objective of the present study is to develop and validate PK of sustained release formulation 
containing Isradipine. The plasma samples of Isradipine were extracted using the protein 
precipitation technique (PPT). The detection wavelength of Isradipine, which was 325nm, was 
determined using UV spectrophotometer. Reversed phase Thermos c18 column was used for 
separation. 10mM ammonium acetate buffer (pH 4) and acetonitrile at a ratio of 20:80% v/v was 
used as the mobile phase with the flow rate of 1.0 ml/min. The linearity achieved in this method was 
in the range of 10-120 ng/ml. HPLC method provides extremely precise results and is an excellent 
and efficient method compared to others. The development of a sustained release formulation offers 
advantages such as prolonged blood levels of the drug and improved patient compliance. The 
formulated sustained release tablets containing Isradipine is capable of exhibiting sustained release 
properties, stable and feasible for industrial scale production. Thus they are capable of reducing the 
dose intake, minimize the blood level oscillations, dose related adverse effects, cost and ultimately 
improve the patient compliance in the hypertension. 
Keywords: Isradipine, Sustained release formulation, bioavailability studies.
Introduction 
Isradipine is 3,5-Pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-
1,4-dihydro-2,6-dimethyl-,methyl 1-methylethyl ester which is  a 
dihydropyridine calcium channel blocker. Its pharmacodynamic 
effects include dilating effects in arterioles which reduce systemic 
resistance and lower blood pressure, with a small increase in 
resting heart rate. [1, 2]  
Only a limited number of analytical and bio-analytical methods 
have been reported for the quantification of Isradipine in various 
matrices. In this research, we have formulated sustained-release 
tablet of Isradipine. A drug delivery system (DDS) is defined as a 
formulation or a device that enables the introduction of a 
therapeutic substance in the body and improves its efficacy and 
safety by controlling the rate, time, and place of release of drugs in 
the body. [3] 
Sustained release, sustained action, prolong action, controlled 
release, extended action, depot are terms used to identify drug 
delivery systems that are designed to achieve prolong therapeutic 
effect by continuously releasing medication over an extended 
period of time after administration of single dose. In the case of 
orally administer this period is measured in hours while in the case 
of injectables this period varies from days to months.[4] Sustain 
release with the introduction of extended release matrix tablet have 
proved to be an effective tool to control the release of drug without 
involving the complex production procedures. By the sustained 
release method therapeutically effective concentration can be 
achieved in the systemic circulation over an extended period of 
time, thus achieving better compliance of patients. Numerous 
sustain release oral dosage forms such as membrane controlled 
system, matrices with water soluble/insoluble polymers or waxes 
and osmotic systems have been developed, intense research has 
recently focused on the designation of SR systems for poorly water 
soluble drugs. However generating such a system requires certain 
consideration of which the half life and the pharmacological action 
of the drug form an essential part.[5] It is desirable that the duration 
of drug action becomes more a design property of a rate controlled 
dosage form and less or not at all a property of the drug moleculeÊs 
inherent kinetic properties. Thus, optimal design of a sustained/ 
controlled release system necessitates a thorough understanding 
of the pharmacokinetics and pharmacodynamics of the drug. When 
the drug is administered in a conventional dosage form, it results in 
a fluctuation of drug concentration at the site of action (peak and 
valley pattern) and therefore in systemic circulation and tissue 
compartment.[6] The advantages of sustained-release formulation 
include reduced dose frequency and improved compliance. It also 
has a reduced side-effect profile especially those related to rapid 
rise in peak serum concentration and local irritation due to a slow 
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release or targeted nature of delivery, resulting in some cases in 
reduced local irritation and a steady rise in serum levels. [7, 8] 
Bioavailability is one of the essential tools in pharmacokinetics, as 
bioavailability must be considered when calculating dosages for 
non-intravenous routes of administration.[9, 10] Bioavailability 
studies are designed to determine either an absolute bioavailability 
(relative to an IV formulation) or relative bioavailability (with an 
alternate reference dosage form with good absorption 
characteristics).[11] They can be used to compare different routes 
of administration, for example oral versus IV or IP versus IM. 
Bioequivalence studies are designed to compare drug products. 
The objective is to determine if these products are bioequivalent. 
The dosage forms should be similar, especially the route of 
administration.[12] The purpose of bioequivalence studies is to 
reduce toxicological studies and full-scale clinical trials to prove 
that the product is of good quality, safe and effective. 
Bioequivalence studies are typically performed after minor changes 
of a marketed product or by manufacturers of generic drugs. [13] 
Chromatography is a technique by which a mixture sample is 
separated into components.[14] High-performance liquid 
chromatography (HPLC), which is used in this research, is also 
referred to as high-pressure liquid chromatography. It is a 
technique in analytic chemistry used to separate the components in 
a mixture, to identify each component, and to quantify each 
component.[15] HPLC relies on pumps to pass a pressurized liquid 
and a sample mixture through a column filled with a sorbent, 
leading to the separation of the sample components.[16] This gives 
HPLC superior resolving power when separating mixtures, which is 
why it is a popular chromatographic technique. [17] Reversed 
phase HPLC is the most commonly used form of HPLC. Reverse 
phase is the choice for the majority of samples, but if acidic or 
basic analytes are present then reverse phase ion suppression (for 
weak acids or bases) or reverse phase ion pairing (for strong acids 
or bases) should be used. [18-21] 
Materials And Methods 
Reagents and Chemicals Used  
Isradipine, Methanol (Merck), Acetonitrile (QReC), Tricholoroacetic 
acid  (Bendosen), Ammonium acetate (Bendosen), Ortho-
phosphoric acid (QReC), Microcrystalline cellulose (Merck), 
Hydroxypropyl methylcellulose (R&M), Talc (Unilab Chemical), 
Magnesium stearate (R&M), Sodium citrate (Bendosen), Xylene 
(BDH Prolabo), Sodium chloride (Bendosen) 
Development of In vitro Dissolution Methods  
The release characteristics of test and reference formulations of 
Isradipine were determined using USP XXIII dissolution apparatus 
(type II, paddle) at 50 rpm. The dissolution medium used 
phosphate buffers pH 6.8 maintained at 37μ0.5■C. Dissolution tests 
were performed on six tablets. Five ml of the samples were 
withdrawn at 0.0, 1.0, 3.0, 5.0, 7.0, 7.5, 8.0, 8.5, 9, 10, 14.0, 18.0 
and 24.0 h time intervals. Equal quantity of the dissolution medium 
was replaced to the dissolution jar after each sampling. Percentage 
drug release and cumulative release at various time intervals were 
calculated and compared. 
Preparation of Standard and Sample Isradipine 
Solutions  
Standard Stock Solution of Isradipine 
10 mg of Isradipine working standard was accurately weighed and 
transferred into a 10 ml volumetric flask and dissolved in methanol 
- water mixture (1:1) and made up to the volume with the same 
solvent to produce a 1mg/ml of isradipine.   The stock solution was 
stored in refrigerator at ă20 μ 20 C until analysis.The stock solution 
was diluted to suitable concentrations for spiking plasma to obtain 
calibration curve (CC) standards and quality control (QC) samples. 
Calibration Curve Standards and Quality Control 
Samples 
Calibration standards for control plasma were prepared by spiking 
this stock solution to obtain the concentration levels of 10, 20, 40, 
60, 80 and 120 ng/ml in human plasma. Quality control samples 
were prepared as bulk, at a concentration of 10 ng/ml (LQC), 60 
ng/ml (MQC) and 120 ng/ml (HQC).These samples were stored 
below -50C until use.   
Plasma Samples 
Calibration standards, validation QC samples and healthy 
volunteer plasma samples were prepared by adding 0.5 ml plasma 
to 2.0ml centrifuge tube and 0.5 ml of precipitating agent (10% w/v 
tricholoroacetic acid) was added and then vortex for 2 min. The 
resulting solution was centrifuged at 4000 rpm for 7 min. The 
supernatant layer was separated and estimated by HPLC. 
Chromatographic Conditions 
Reversed phase HPLC method was chosen for Isradipine.  
The standard solutions of Isradipine were scanned from 200ă400 
nm and the UV spectra obtained were recorded. From the UV 
spectra, the detection wavelength selected was 325 nm for 
Isradipine respectively. 10mM ammonium acetate buffer (pH 4) 
and acetonitrile at a ratio of 20:80% v/v was used as the mobile 
phase with the flow rate of 1.0 ml/min. Reversed phase Thermos 
c18 column was used as the stationary phase.  
Validation of HPLC methods 
Validation parameters tested were, selectivity/specificity, 
sensitivity, linearity, precision, accuracy, stabilities, recovery, 
ruggedness and robustness. 
Selectivity/ Specificity 
In order to prove that the method chosen was specific and 
selective the following two sets of samples (blank samples and 
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samples containing analyte and internal standard) were processed 
and injected into the HPLC using the extraction procedure.  
Sensitivity 
The lower limit of quantification for Isradipine 10 ng/ml. 
Linearity 
The calibration curve was plotted using response factor and 
concentration of the standard solutions. Linearity was established 
using four calibration curves over the range of (10 to 120 ng/ml for 
Isradipine) using the weighted least square regression analysis. 
Precision and Accuracy 
The precision and accuracy of the method was determined by 
analyzing two batches each consisting of one set of calibration 
curve with  six replicates of quality control samples at four 
concentration levels [Quality Control samples at Low (QCL), Middle 
(QCM) and High(QCH)].  
Stability Studies 
Various stability studies were carried out. Room temperature stock 
solution stability, refrigerated stock solution stability, freeze thaw 
stability, bench top stability, short term stability and long term 
stability were determined. The short term stability of stock dilutions 
of analyte was evaluated at room temperature. Aqueous stock 
dilution of the analyte was prepared.  One portion of the stock 
dilution was placed in the refrigerator between 2-8ĈC, while the 
other portion was placed at room temperature for 24 h. Stock 
dilution stored at room temperature (stability samples) was 
compared with refrigerated stock dilutions considered as 
Âcomparison samplesÊ. Six replicate injections of the above 
solutions were made. The long term stability of the stock solution 
when stored in the refrigerator for a given period of time was 
determined.  Stock solutions of the analyte was prepared and 
stored in the refrigerator between 2 - 8ĈC for 7 days (stability 
stock).  The stock solution stabilities of the analyte was determined 
with a comparison stock solution, which was prepared freshly. Five 
replicate injections of the above solutions were made.  The 
response of comparison samples were corrected by multiplying 
with correction factor to nullify the difference between the 
measured weights or the dilutions made. The freeze thaw stability 
test was done to ensure that the analyte was stable in the 
biological matrix even after multiple freeze-thaw cycles. The bench 
top stability study was carried out using six quality control samples 
each at Quality Control sample at Low concentration (QCL) and 
Quality Control sample at High concentration (QCH) levels were 
stored at room temperature for 3 and 6 h. In long-term stability 
study, six samples of each quality control samples at low and high 
concentrations were stored below -50ĈC in the deep freezer. The 
stability of the analyte was evaluated by comparing each of the 
back calculated concentrations of stability Quality Control sample 
(QCs) with the mean concentrations of the respective QCs 
analyzed in the first  accepted  precision  and  accuracy batch . To 
evaluate the stability of the samples in the autosampler after 
processing for the anticipated run time, six sets of quality control 
samples each at low and high concentrations were placed in the 
auto sampler for 24 h and 48 h.  
Recovery 
To determine recovery of this method, six replicates of aqueous 
quality control samples (un extracted) with concentrations close to 
spiked Quality Control sample at Low concentration (QCL), Quality 
Control sample at Middle concentration (QCM) and Quality Control 
sample at High concentration (QCH) concentration (extracted) 
were prepared. These un-extracted samples were injected along 
with precision and accuracy batch. 
Ruggedness 
Ruggedness of the method was studied by changing the 
experimental conditions such as operators, instruments, source of 
reagents, solvents and column of similar type. Chromatographic 
parameters such as retention time, asymmetric factor, capacity 
factor and selectivity factor were evaluated. 
Robustness 
Robustness of the method was studied by injecting the standard 
solutions with slight variations in the optimized conditions namely, 
μ 1% in the ratio of acetonitrile in the mobile phase, μ 0.5 units in 
the pH of the buffer, μ 0.5 ml volume of the triethylamine in 
aqueous phase and μ 0.1 ml of the flow rate.  
Method of analysis 
The processed standards and samples were analysed using 
optimised chromatographic conditions mentioned earlier and the 
chromatograms were recorded. The quantification of the 
chromatogram was performed using peak area ratios (response 
factor) of the drug. The calibration curves were constructed 
routinely during the process of pre-study validation and in-study 
validation. 
Animal Information 
Four healthy, adult, either gender of New Zealand White Rabbits, 
weighing 2 ă 2.5 kg was obtained from Central Animal house, 
Universiti Sains Malaysia, Penang, Malaysia.  The animals were 
housed in large, spacious rabbit cages at an ambient room 
temperature with 12-h-light/12-h-dark cycle.  The animals were fed 
with water and normal rabbit pellet fed, green leaves vegetables ad 
libitum. The animal experiment protocol was approved by the 
Institutional Animal Ethical Committee of AIMST ( AUHAEC 
9/FOP/2013 ) and the study was carried out according to Animal 
Research Review Panel (ARRP) guidelines.  
In vivo data analysis  
The pharmacokinetic parameters Cmax, tmax, AUC0-t, AUC0-¥, t1/2 and 
kel were determined using WinNonlin Standard edition version 5.1 
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for individual drug treatments from the observed plasma 
concentration-time data.  
Statistical Analysis 
Statistical analysis was performed using a SPSS Version 13.0. The 
pharmacokinetic parameters like Cmax, Tmax, tó, Kel, AUC0-t and 
AUC0-¥ of both formulations are presented in Mean μ S.D. One way 
ANOVA (Analysis of Variance) was employed in the statistical 
analysis of the determined parameters in this study. Statistical 
significance was defined at P<0.05. 
Results And Discussion 
Evaluation of Compression 
The sustained release tablets were prepared by direct compression 
technique. The powder of nine different formulations were 
evaluated for angle of repose, loose bulk density (LBD) and tapped 
bulk density (TBD) as shown in Table 1 of Isradipine.  
    Table 1 Formulation prepared by direct compression method (F1-F9) for Isradipine  
Fa Isradipine MCC HPMC Ethyl Cellulose Talc Magnesium Stearate  Total (mg/tab)
F1 5 145 20 20 5 5 200 
F2 5 155 15 15 5 5 200 
F3 5 165 10 10 5 5 200 
F4 5 145 40 - 5 5 200 
F5 5 155 30 - 5 5 200 
F6 5 165 20 - 5 5 200 
F7 5 145 - 40 5 5 200 
F8 5 155 - 30 5 5 200 
F9 5 165 - 20 5 5 200 
a Code of formulations  
Tablet Manufacture 
Development of Isradipine SR tablets 
The physical properties of different batches of developed tablets 
are given in Table 2 & 3 (Figure 1) of Isradipine respectively. All the 
batches showed uniform thickness. The average percentage 
deviation of 20 tablets of each formula was less than μ 5% and 
hence all formulations passed the test for uniformity of weight as 
per official requirements (Pharmacopoeia of India 1996). Good 
uniformity content was found among three different batches of 
tablets. Another measure of tablets strength is friability. In the 
present study, the percentage friability for all the formulations was 
below 1%, indicating that the friability is within the prescribed limits. 
All the tablets formulations showed acceptable pharmaco technical 
properties and complied with the specifications for weight variation, 
drug content, hardness and friability. 
 
   Table 2 Comparison of the physical properties of the matrix tablets containing Isradipine 
 
a Code of formulations 
b Results represents the mean of replicate determination with the standard deviation given in parenthesis 
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Table 3 Granule properties of the different formulations of 
Isradipine 
 
aCode of formulations. 
bLoose Bulk Density.   
cTapped Bulk Density 
 
 
 Figure 1: Photograph of Isradipine sustained release tablets 
In vitro Release  
All the batches have shown that as the polymer concentration 
increases, the drug release rate decreases for Isradipine. (Figure 
2). The dissolution of the marketed IR tablets indicated that more 
than 80% of the drug is released within 1h, which complies with the 
pharmacopoeial specifications. In all the batches, we observed that 
as the polymer concentration increases, the drug release rate 
decreases. The mechanism of drug release from these 
formulations is clearly revealed in Figure 3-6 for Isradipine. In vivo 
studies were carried out for the optimized formulation in six healthy 
rabbits and the pharmacokinetic studies were carried out for the 
optimized formulation and compared with the marketed 
formulation. 
Kinetics and Mechanism of Drug Release  
The in vitro drug release profiles were plotted according to zero ă 
order, first- order, Higuchi and Peppas equations to understand the 
mechanism of drug release and to compare the differences in the 
release profile of optimized batches of Isradipine tablets (Figure 4-
7) respectively. 
Pharmacokinetic Data 
The order of treatment administration was randomized in two 
sequences (AB and BA) in blocks of two.  In each dosing session, 
volunteers received Reference Product A (Immediate release 
formulations) and Test B (Sustained release formulations). A wash 
out period of seven days was allowed between dose 
administrations. Blood samples (4 ml) were collected at 0 (before 
drug administration) 0.0, 1.0, 3.0, 5.0, 7.0, 7.5, 8.0, 8.5, 9.0, 10.0, 
14.0, 18.0 and 24.0 h post dosing. The samples were centrifuged 
and plasma was separated. There were no serious adverse effects 
observed during the entire study.  
Estimation of the Selected Drugs in Rabbit Plasma 
Optimization of Chromatographic Conditions 
The standard solutions were analyzed using the initial 
chromatographic conditions.  To improve the resolution or 
symmetry of the peaks or to study the effect of the other 
chromatographic conditions, the chromatographic variables like pH 
of the mobile phase, the nature of stationary phase,  
the composition of the mobile phase and flow rate were optimized 
(Figure 7).  
 
Muralidharan, International Journal of Drug Delivery 7 (3) 126-140 [2015] 
 
 
  
PAGE | 131 |
 
 
Figure 3: Zero order chart of optimized Isradipine formulation (F5) 
 
Figure 4: First order chart of optimized Isradipine formulation (F5) 
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Figure 5: Higuchi chart of optimized Isradipine formulation (F5) 
 
Figure 6: Peppas chart of optimized Isradipine (F5) 
 
Figure 7: Typical chromatogram of standard solution of Isradipine 
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Specificity 
HPLC-UV analysis of the blank human plasma samples showed 
the separations of Isradipine, no interference with either of these 
were observed. Hence the specificity of the method was 
established by comparison with human plasma (control). 
Representative chromatograms of extracted blank plasma 
indicating no interference in the blank plasma and in drug-free 
human plasma at the retention time of 5.5 for the drug Isradipine 
(Figure 8).  
 
 Figure 8: Typical chromatogram of blank rabbit plasma 
Sensitivity  
The Lower limit of quantification for Isradipine 10 ng/ml. 
Linearity  
The linearity range for Isradipine was found to be 10, 20, 40, 60, 80 
and 120 ng/ml. The results are given in Table 4 and is shown in 
Figure 9 with correlation coefficient (r2) was greater than 0.99.  
Table 4 Concentrations-response linearity data for Isradipine 
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Figure  9: Calibration curve of Isradipine 
Precision and Accuracy 
The precision of the assay was measured by the percent 
coefficient of variation over the concentration range of LOQ, low, 
middle and high quality control sample of Isradipine during the 
course of validation. The accuracy of the assay was defined as the 
absolute value of the ratio of the calculated mean values of the 
LOQ, low, middle and high quality control samples to their 
respective nominal values, expressed as percent. The results are 
given in Table 5a ă 5c. 
 
Table 5a Within Batch Precision and Accuracy for Isradipine 
 Nominal Concentration (øg/ml) 
 LQC MQC HQC 
 10 40 120 
1 8.9451 39.6248 119.3267 
2 9.0534 39.5201 118.942 
3 9.5368 38.9751 119.365 
4 9.0147 39.0548 118.2341 
5 8.9957 39.884 119.0318 
Mean 9.10914 39.41176 118.9799 
S.D (μ) 0.242228 0.386726 0.455225 
C.V (%) 2.65917 0.981244 0.382607 
% Nominal 91.0914 98.5294 99.14993 
 
 
 
Table 5b Between Batch / Inter day Precision and Accuracy for 
Isradipine 
Nominal Concentration (øg/ml)
LQC MQC HQC
10 40 120
1 9.6524 39.5248 119.6384
2 8.9967 38.0358 119.3057
3 9.4217 39.2547 119.8637
4 8.9936 38.9932 119.8527
5 9.3542 39.7542 118.9075
Mean 9.28372 39.11254 119.5136
S.D (μ) 0.285693 0.666241 0.407343
C.V (%) 3.07735 1.703394 0.340834
% Nominal 92.8372 97.78135 99.59467
N 5 5 5
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Table 5c Intra Day Precision and Accuracy for Isradipine 
 Nominal Concentration (øg/ml) 
 LQC MQC HQC 
 10 40 120 
1 9.6325 39.5241 119.6358
2 8.9421 38.5972 118.4207
3 9.5274 38.9524 118.4562
4 9.0657 39.0547 119.0358
5 8.9427 39.5204 118.6395
Mean 9.22208 39.12976 118.8376
S.D (μ) 0.332627 0.396489 0.508655
C.V (%) 3.606849 1.013267 0.428026
% Nominal 92.2208 97.8244 99.03133
N 5 5 5 
 
Stabilities 
The stability studies of plasma samples spiked with selected drugs 
were subjected to three freeze-thaw cycles, short term stability at 
room temperature for 3 h and  long term stability at ă 70oC over 
four weeks. In addition, stability of standard solutions was 
performed at room temperature for 6 h and freeze condition for four 
weeks. The mean concentrations of the stability samples were 
compared to the theoretical concentrations. The results indicate 
that selected drugs in plasma samples can be stored for a month 
without degradation in frozen state. The results of short term 
storage at room temperature stability and freeze-thaw cycles 
indicate no degradation of selected drugs in plasma as well as in 
sample solution and hence plasma samples could be handled 
without special precautions. The results are given in Table 6a -6f. 
 
Table 6a Stock Stability of Isradipine 
 
   
           Table 6b 20ĈC Stability of Isradipine in plasma 
 
 
Table 6c Short Term Room Temperature Stability of Isradipine 
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Table 6d Auto sampler Stability of Isradipine in plasma 
 
Table 6e Freeze/thaw cycle stability of Isradipine 
 
 
 
 
 
Table 6f Long term stability for four weeks of Isradipine 
 
Recovery  
The detailed results are presented in Table 7. The results indicate 
that the recovery of Isradipine was consistent at all levels (Figure 
10). 
Ruggedness and Robustness 
No significant changes in the chromatographic parameters were 
observed when changing the experimental conditions (operators, 
instruments, source of reagents and column of similar type) and 
optimized conditions (pH, mobile phase ratio and flow rate).   
Estimation of Selected Drugs in Plasma Samples 
The calibration curve samples (CC samples), quality control 
samples (QC samples) and plasma sample solutions were injected 
with the optimized & validated chromatographic conditions and the 
chromatograms were recorded. The individual and mean 
concentration of the drugs present in the plasma samples were 
calculated and are presented in the Tables 8-9 (Figure 11). 
In vivo Data Analysis 
Pharmacokinetic parameters such as peak plasma concentration 
(Cmax), time to peak concentration (tmax), area under the plasma 
concentration-time curve (AUC0-t & AUC0-¥), elimination rate 
constant (kel) and elimination half-life (t1/2) were calculated 
separately and the blood level data of selected formulations were 
compared. Mean plasma concentration-time profile of Isradipine 
was given in Table 10 and Figure 12. 
Statistical Analysis  
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The pharmacokinetic parameters of different drug formulations of 
isradipine were compared statistically by one way ANOVA 
(analysis of variance) using SPSS version 16.0. P-value of <0.05 
was considered as statistically significant. The results were 
expressed as the mean μ S.D. The pharmacokinetic parameters 
Cmax, AUC0-t and AUC0-∞ of the immediate release and sustained 
release formulations of Isradipine was found to be significantly 
different by one way ANOVA. 
 
Figure 10: Typical chromatogram of spiked rabbit plasma 
 
Figure 11: Typical chromatogram of Isradipine rabbit sample  
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Figure 12: Mean plasma concentration-time profile of Isradipine from developed Sustained release tablets (test) and marketed immediate release 
tablet (Reference) 
 
Table 7 Recovery study of Isradipine 
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   Table 8 Individual plasma concentrations (øg/ml) and pharmacokinetic parameters for Isradipine immediate release product 
 
Table 9 Individual plasma concentrations (øg/ml) and pharmacokinetic parameters for Isradipine sustained release product 
 
Table 10 Mean plasma concentrations (øg/ml) for Isradipine 
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Conclusion 
A simple and sensitive method for the determination of Isradipine in 
plasma by HPLC was developed and validated. Adequate 
specificity, precision and accuracy of the proposed method were 
demonstrated over the concentration range of 10.0 ă 120.0 ng/ml. 
The method was accurate, reproducible, specific and applicable to 
the evaluation of pharmacokinetic profiles of Isradipine and suitable 
for the pharmacokinetic study of Isradipine. 
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